Adaptive Ad Systems (OTC:AATV) Stock, Quote.Headers.trade-ideas

Adaptive Ad Systems Inc is engaged in the cable television and online media advertising business. The company provides competitive ad-insertion technology solutions and ad sales for cable, broadcast, networks, and other video operators such as universities, master-planned communities, and apartments. Its services include acquiring advertising sales from local, regional, and national advertisers, scheduling, and traffic and billing.

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy
84% of immune responses were de novo, observed in patients without pre-existing T-cell activity against encoded cancer antigens
CVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicities
Most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection
100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollment
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 13, 2024 / CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today presented compelling data from the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study in patients with glioblastoma at the European Society for Medical Oncology (ESMO) Congress. The presented data include safety, tolerability and initial immunogenicity data provided for all evaluable patients treated within Part A of the trial with CVGBM dose levels of 12-100 µg. The presentation can be reviewed <a href="https://pr.report/2kol">here</a>.

Biotech

News

General

CVAC

CureVac's CVGBM Cancer Vaccine Induces Immune Responses In Phase 1 Study In Glioblastoma Presented At The ESMO 2024 Congress; Preliminary Immunogenicity Results Demonstrate Induction Of Cancer Antigen-Specific T-Cell Responses In 77% Of Evaluable Patients Following CVGBM Monotherapy

Lifeist Wellness Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LFSWF#OTC">LFSWF</a>) announced Thursday it completed the <a href="https://www.benzinga.com/markets/cannabis/24/06/39501062/simply-solventless-to-acquire-cannmart-as-it-seeks-to-expand-into-hydrocarbon-cannabis-concentra">previously announced sale</a> of CannMart's shares to Simply Solventless Concentrates Ltd. 
CannMart is a business-to-business wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards.
&#8220;We are pleased to announce the successful completion of the sale of CannMart to Simply Solventless Concentrates, a company whose track record of profitability and operational excellence has continually impressed us,&#8221; stated Meni Morim, CEO of Lifeist. 
&#8220;This transaction not only ensures that CannMart is in capable hands but also allows Lifeist to sharpen its focus on our core mission of transforming human wellness,&#8221; Morim added. &#8220;We believe that this sale represents a strategic win for our shareholders, as it positions Lifeist to allocate more resources towards growing Mikra while still benefiting from Simply Solventless&#8217; continued success in the cannabis market.&#8221;
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Lifeist obtained shareholder approval to complete the sale of CannMart during a meeting held on Sep. 5, 2024. It also received approval of the TSX Venture Exchange to close the said transaction.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40441925/lifeists-u-turn-on-plan-to-move-away-from-cannabis-industry-as-it-buys-vaporizer-technology">Lifeist&#8217;s U-Turn On Plan To Move Away From Cannabis Industry As It Buys Vaporizer Technology</a>
As part of the deal, Lifeist received the following at closing:
<ul>
<li>$500,000 cash payment and 2 million units of Simply Solventless worth also $500,000. Each unit includes one common share in SSC and half of a warrant. The full warrant grants Lifeist the option to purchase one Simply Solventless share at $0.40 for up to 24 months from the issuance date.</li>
</ul>
<ul>
<li>A promissory note (the VTB loan), secured by CannMart's assets, for $1.7 million. The loan carries a 3% annual interest rate and will be repaid in monthly installments starting on Oct. 1, 2024. These payments vary in amount. They begin with $100,000 in October and increase to $400,000 in November. They reduce to $150,000 and $100,000 in subsequent months, until the loan is fully repaid.</li>
</ul>
The VTB loan is also subject to a 20% upward adjustment if CannMart's quarterly gross revenue exceeds $3 million for its existing brands in the four fiscal quarters immediately following June 25, 2024.
Price Action: Lifeist shares closed Thursday's market session 0.76% higher at $0.06 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40838052/cannabis-retail-giant-high-tide-ramps-up-offering-for-millions-of-customers">Cannabis Retail Giant High Tide Ramps Up Offering For Millions Of Customers</a></li>
</ul>
Photo: Courtesy of Esteban López on Unsplash

Cannabis

LFSWF

Lifeist Sells CannMart To Simply Solventless To Focus On Its 'Core Mission Of Transforming Human Wellness'

WIIM

RH shares are trading higher after the company reported better-than-expected Q2 financial results. Multiple analysts raised their price targets following the report.

The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) today reported the following results for the month ended August&nbsp;31, 2024: &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">August</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>(millions, except per share amounts and ratios; unaudited)</td>
<td>2024</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net premiums written</td>
<td>$</td>
<td>6,507.1</td>
</tr>
<tr>
<td>Net premiums earned</td>
<td>$</td>
<td>5,967.9</td>
</tr>
<tr>
<td>Net income</td>
<td>$</td>
<td>935.3</td>
</tr>
<tr>
<td>Per share available to common shareholders</td>
<td>$</td>
<td>1.59</td>
</tr>
<tr>
<td>Total pretax net realized gains (losses) on securities</td>
<td>$</td>
<td>104.0</td>
</tr>
<tr>
<td>Combined ratio – current year</td>
<td>85.5</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;– prior year month</td>
<td>97.2</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Average diluted equivalent common shares</td>
<td>587.6</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Earnings

Progressive Reports August 2024 EPS $1.59; Net Premiums Written $6.507B

Boeing shares are trading lower after workers rejected the proposed labor contract with the company, leading to a strike.

Italian automaker Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) will reportedly halt the production of its <a href="https://www.benzinga.com/news/23/12/36147589/stellantis-new-fiat-500e-ev-might-just-be-the-antidote-to-bulky-e-suv-trend-report">electric Fiat 500</a> for four weeks starting Friday at the Mirafiori factory in Turin due to a lack of demand in the European market.
What Happened: "The measure is necessary due to the current lack of orders linked to the profound difficulties experienced in the European electric [car] market by all producers, particularly the European ones,&#8221; the company <a href="https://www.theguardian.com/business/2024/sep/12/production-of-electric-fiat-500-halted-lack-of-european-orders-stellantis">told</a> The Guardian. The company added that it is working &#8220;hard&#8221; to manage the transition. 
The company will also reportedly invest 100 million euros into the Mirafiori plant to adopt a higher-performance battery and produce a hybrid version of the electric 500 model between 2025 and 2026.
Why It Matters: The 500e is a small electric car from Stellantis&#8217; Fiat brand. It<a href="https://www.benzinga.com/news/24/05/39078641/legacy-auto-giants-gm-stellantis-plan-to-fend-off-chinese-ev-threat-with-25k-electric-jeep-most-affo"> starts at </a>$32,500 in the U.S. and at about 25,000 euros currently in Italy. 
In the first half of 2024, 660,200 units of Fiat vehicles were sold, marking an increase of 2.2% from last year. 
Europe is the brand&#8217;s key market where it had 95,779 registrations in the period.
However, the broader European EV market has been facing a slump for a while now as dwindling incentives and higher vehicle prices, combined with increasing competition from Chinese companies, pour cold water over the block&#8217;s climate goals.
In reaction to the growing Chinese threat, the EU <a href="https://www.benzinga.com/news/24/06/39306681/fresh-eu-tariffs-could-slow-down-tesla-chinese-rivals-but-warren-buffett-backed-byd-can-profitably-e">introduced tariffs</a> on China-made EVs while <a href="https://www.benzinga.com/news/24/08/40479832/elon-musks-tesla-gets-a-breather-as-eu-slashes-tariffs-on-its-china-made-evs-even-as-saic-geely-and">carving out a lower rate</a> for Elon Musk&#8217;s Tesla Inc. China <a href="https://www.benzinga.com/news/24/08/40484760/china-hits-back-at-eus-unfair-ev-tariffs-that-gave-relief-to-chinese-made-tesla-will-take-all-necess">termed these tariffs</a> as &#8220;unfair.&#8221;
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40849409/former-top-gear-host-james-may-thinks-a-vehicle-the-size-of-a-fiat-panda-but-styled-like-tesla-cyber" target="_blank" rel="noreferrer noopener">Former Top Gear Host James May Thinks A Vehicle The Size Of A Fiat Panda But Styled Like Tesla Cybertruck Might Look ‘Fantastic'</a></li>
</ul>
Photo courtesy: Stellantis

Global

Tech

Media

STLA

Stellantis To Stop Fiat 500e Production For 4 Weeks In Italy Due To 'Profound Difficulties' In European EV Market

Shares of furniture and home goods companies are trading higher in possible sympathy with RH after the company reported Q2 financial results.

On Thursday, Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) released initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer as part of its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40842506/immuneering-announces-positive-initial-phase-2a-data-including-complete-and-partial-responses-with" rel="noreferrer noopener">ongoing Phase 2a trial</a>.
The first two patients in the Phase 2a arm evaluating IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer have recorded complete or partial responses for an initial response rate of 40% (2/5) and disease control rate of 80% (4/5), with the other three patients earlier in the course of treatment and all five continuing on treatment.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37758012/cancer-treatment-focused-immuneering-faces-analyst-downgrades-who-cite-underwhelmin" rel="noreferrer noopener">Cancer Treatment-Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data</a>.
The Phase 3 MPACT study established benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients.
The study included one Complete Response (CR) out of 431 patients, a 23% Overall Response Rate, and a 48% Disease Control Rate.
Benchmarks for modified (m) Gemcitabine/nab-Paclitaxel include an 18.6% ORR2.
To date, the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel has been observed to be well tolerated.
Based on safety data to date, the trial&#8217;s Data and Safety Monitoring Board (DSMB) has approved enrolling additional patients into this arm at 320mg QD p.o., the first of which have already been dosed and are awaiting first scans.
In the Phase 2a portion of Immuneering&#8217;s ongoing IMM-1-104 Phase 1/2a clinical trial, IMM-1-104 is being evaluated as both monotherapy and in combination with approved chemotherapeutic agents.
Immuneering previously announced that IMM-1-104 received fast-track designation for first- and second-line pancreatic cancer.
In March, Immuneering revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37710266/whats-going-on-with-cancer-focused-immuneering-stock-on-thursday" rel="noreferrer noopener">RAS-mutant solid tumors</a>.
Price Action: At last check on Friday, IMRX stock was up 49% at $2.13 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40850606/occidentals-1pointfive-secures-500m-boost-to-capture-co2-details" target="_blank" rel="noreferrer noopener">Occidental&#8217;s 1PointFive Secures $500M Boost To Capture CO2: Details</a>.</li>
</ul>

Health Care

Movers

IMRX

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) confirmed Thursday it has completed the <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">previously announced</a> acquisition of Atwater Brewery, from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>).
&#8220;Atwater Brewery is a renowned craft brewery with a rich history and a loyal following in Michigan," said Irwin D. Simon, chairman and chief executive officer of Tilray Brands. "This acquisition expands our reach in the Great Lakes region and further strengthens our position in the craft beer industry. We are excited to welcome Atwater Brewery to Tilray Brands and are committed to leveraging our expertise and resources to drive growth, expand distribution, and provide beer lovers with access to Atwater&#8217;s exceptional brews."
TD Securities acted as financial advisor, and DLA Piper LLP (US) acted as external legal counsel to Tilray Brands.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out
The Atwater Brewery acquisition comes on the heels of finalized purchases of craft breweries Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing, also from Molson.
Over the last several months, Tilray, <a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag" target="_blank" rel="noreferrer noopener">valued</a> at $2 billion, has been expanding its U.S. brewery business but is not giving up on cannabis. In August, it <a href="https://www.benzinga.com/markets/cannabis/24/08/40510926/tilray-is-not-giving-up-on-cannabis-ramps-up-its-canadian-portfolio-on-heels-of-buying-four-us-b">released its latest small-batch flower strain</a>, Milk &amp; Cookies, under its premium cannabis brand Broken Coast, and in September, it published the results of a study focused on cannabis as a potential treatment for pain management and <a href="https://www.benzinga.com/markets/cannabis/24/09/40774179/cannabinoid-treatment-significantly-reduces-fibromyalgia-pain-and-improves-quality-of-life-new-t">other fibromyalgia-associated symptoms</a>.
Moreover, the Canadian cannabis giant is also working on expanding its medical marijuana business globally and has <a href="https://www.benzinga.com/markets/cannabis/24/08/40325566/these-3-cannabis-companies-hold-cultivation-licenses-in-germany-a-1-8b-market-opportunity" target="_blank" rel="noreferrer noopener">already obtained a cultivation license</a> in Germany, whose market is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37896976/cannabis-stocks-set-to-dominate-germanys-new-market-a-surge-in-demand-meets-establi" target="_blank" rel="noreferrer noopener">projected</a> to reach a valuation of approximately €1.7 billion ($1.86 billion) by 2025​.
Tilray Brands' beverage portfolio includes famed craft beer, spirits and non-alcohol beverage brands such as SweetWater Brewing Company, Montauk Brewing Company, Alpine Beer Company, Green Flash Brewing Company, Shock Top, Breckenridge Brewery, Breckenridge Distillery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewing Company, Widmer Brothers Brewing, Square Mile Cider Company, HiBall Energy, Happy Flower CBD along with Canada&#8217;s top recreational cannabis and THC beverage brands Mollo and XMG.
Price Action: Tilray shares closed Thursday's market session 1.16% lower at $1.70 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39539050/is-tilrays-2b-valuation-just-the-beginning-analyst-sees-10b-market-opportunity-initiates-coverag">Is Tilray Really Worth $2B? Analysts Sees Path To $10B Market Opportunity</a></li>
</ul>
Photo: Courtesy of Lucas via Pexels

TLRY

Billion-Dollar Marijuana Giant Buys Another Brewery From Molson Coors, Expands Great Lakes Footprint

Oppenheimer analyst Chris Kotowski maintains Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) with a Outperform and raises the price target from $64 to $66.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Jefferies Financial Gr, Raises Price Target to $66

CLSA initiates coverage on NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) with a Outperform rating and announces Price Target of $11.

Initiation

CLSA Initiates Coverage On NuScale Power with Outperform Rating, Announces Price Target of $11

Record date set for September 23, 2024
Distribution date and closing date for spin-off and merger with Amentum set for September 27, 2024
Amazon Holdco Inc. to be renamed "Amentum Holdings, Inc.," effective as of the completion of the spin-off and merger
DALLAS, Sept. 13, 2024 /PRNewswire/ -- Jacobs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) announced today that its Board of Directors has set the close of business on September 23, 2024, as the record date for the spin-off distribution of its Critical Mission Solutions and Cyber &amp; Intelligence government services businesses. The spin-off is part of Jacobs' <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4253984-1&amp;h=3315499896&amp;u=https%3A%2F%2Fwww.jacobs.com%2Fnewsroom%2Fpress-release%2Fjacobs-spin-off-and-merge-its-critical-mission-solutions&amp;a=previously+announced+plan">previously announced plan</a> to separate these businesses and merge them with Amentum in a Reverse Morris Trust transaction. The spin-off and merger are expected to be completed at 4:05 p.m. and 4:10 p.m. Eastern Time, respectively, on September 27, 2024, and will create a new publicly traded company listed on the NYSE named Amentum Holdings, Inc. ("Amentum").&nbsp;

Dividends

Jacobs Solutions Announces Record Date Set For September 23, 2024 And Distribution Date Set For September 27, 2024 For The Spin-Off Of Its Critical Mission Solutions And Cyber & Intelligence Government Services Businesses Named Amentum Holdings, Inc.

OSTX

OS Therapies Announces The Development Of In Vitro Concept Data For Two tADC-Based Therapeutic Candidates Targeting Breast Cancer, Lung Cancer And Gastric Cancer

Loop Capital analyst Laura Champine maintains Caleres (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) with a Hold and lowers the price target from $45 to $30.

Loop Capital Maintains Hold on Caleres, Lowers Price Target to $30

PGRE

Paramount Group Suspends Regular Quarterly Dividend

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is ramping up investment in delivery drivers, committing $2 billion to its delivery services program this year.
This move follows union organizing efforts and will likely raise the average national pay for Amazon drivers to nearly $22 per hour, a 7% increase from last year.
The investment will also bring other benefits, including technology upgrades for drivers, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/tech/amazon-boosts-pay-for-its-drivers-following-threats-to-unionize-8dae38e4?mod=tech_lead_story" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/09/40813281/amazon-aws-to-invest-11b-in-uk-support-14k-jobs-annually" rel="noreferrer noopener">Amazon AWS To Invest $11B in UK, Support 14K Jobs Annually</a>
The pay increase brings the average driver wage up from $20.50 in 2022, with the minimum pay for Amazon drivers now ranging from $19.50 to $25.25 per hour, depending on location.
Amazon does not directly employ drivers but hires local delivery businesses, called Delivery Service Partners, which determine their salaries within Amazon&#8217;s guidelines.
Amazon&#8217;s increased investment in its delivery drivers follows union activity and regulatory scrutiny of its labor practices.
Amazon is also introducing a new app allowing drivers to access their accrued wages more efficiently, providing more flexibility between paydays.
<a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40724090/amazon-declared-joint-employer-of-contracted-delivery-drivers-by-labor-board-paving-the-way-for-" rel="noreferrer noopener">Earlier in 2024</a>, the National Labor Relations Board (NLRB) ruled that Amazon is a &#8220;joint employer&#8221; of some contracted drivers, which could force Amazon to negotiate with unionizing employees. Earlier in 2023, Amazon spent over $3 million on consultants to deter unionization within its delivery network.
Price Action: AMZN stock is up by 0.67% to $188.26 premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40800539/amazon-and-oracle-partnership-unlocks-major-cloud-growth-opportunity-analyst-suggests" target="_blank" rel="noreferrer noopener">Amazon and Oracle Partnership Unlocks Major Cloud Growth Opportunity, Analyst Suggests</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

AMZN

Amazon To Raise Driver Wages Amid Unionization Pressure and NLRB Ruling

Canaccord Genuity analyst Susan Anderson initiates coverage on Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) with a Buy rating and announces Price Target of $18.

NATR

Canaccord Genuity Initiates Coverage On Natures Sunshine Products with Buy Rating, Announces Price Target of $18

APVO

Aptevo Therapeutics Shares Move Higher; Co. And Alligator Bioscience Announce Interim Data From Dose Escalation Phase Of Phase 1 ALG.APV-527 Trial Will Be Presented At ESMO Congress 2024 On Sept. 14

Iveda Solutions, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) announced that it has approved a 1-for-8 reverse stock split of the outstanding and authorized shares of its common stock and corresponding adjustment to the publicly traded common stock purchase warrants.
Pursuant to the reverse stock split, each eight (8) shares of the Company's outstanding common stock, $0.00001 par value per share, will be automatically combined and converted into one (1) outstanding share of common stock. In addition, the current publicly traded common stock purchase warrants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDAW#NASDAQ">IVDAW</a>) will be proportionately adjusted under the current terms of the warrant agreement so that each 8 warrants will be entitled to acquire one share of common stock at a revised purchase price per share of $34.00 ($4.25 per warrant) The split will also reduce the number of the Company's authorized common stock from 37,500,000 shares to 4,687,500 shares.

Stock Split

IVDA

IVDAW

Iveda Solutions Announces 1-For-8 Reverse Stock Split To Be Effective September 17, 2024; Each 8 Warrants Will Be Entitled To Acquire 1 Share Of Common Stock At A Revised Purchase Price Per Share Of $34.00 ($4.25 Per Warrant) The Split Will Also Reduce The Number Of Common Stock From 37.5M Shares To 4,687,500 Shares

Loop Capital analyst Anthony Chukumba maintains Upbound Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPBD#NASDAQ">UPBD</a>) with a Hold and maintains $36 price target.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Adaptive Ad Systems

Adaptive Ad Systems (AATV) Forecast

Adaptive Ad Systems (OTC:AATV) Stock, Quote.Headers.trade-ideas